On March 6, 2023 Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that on March 1, 2023 the Company granted an inducement award to purchase up to 15,200 shares of common stock to one new employee under the Company’s 2023 Inducement Plan (Press release, Syndax, MAR 6, 2023, View Source [SID1234628195]). The stock option has an exercise price per share of $24.86, the closing price of the Company’s common stock on the Nasdaq Global Select Market on March 1, 2023 and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee’s continued service relationship with Syndax through the applicable vesting dates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!